Bristol Myers' Lead Cancer Drug Opdivo Regime Meets Primary Goal In Phase 3 Lung Cancer Study

Bristol Myers Squibb & Co BMY announced interim data from Phase 3 CheckMate -77T trial evaluating the perioperative regimen of neoadjuvant (before surgery) Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo.

Adjuvant treatment is given after the main treatment to reduce the chance of cancer returning by destroying any remaining cancer cells.

The trial met its primary endpoint of improved event-free survival (EFS) as assessed by Blinded Independent Central Review (BICR) in patients with resectable stage IIA to IIIB non-small cell lung cancer (NSCLC). 

Also Read: Bristol-Myers Squibb Plans To Double Clinical Pipeline Platforms To Support Long-Term Sustainable Growth.

The perioperative regimen showed a statistically significant and clinically meaningful improvement in event-free survival (EFS) compared to neoadjuvant chemotherapy and placebo, followed by surgery and adjuvant placebo.

The safety profile of this Opdivo-based regimen was consistent with previously reported studies in NSCLC.

The company will complete a full evaluation of the available data from CheckMate -77T and looks forward to sharing the results with the scientific community at an upcoming medical conference and discussing with health authorities. 

The trial is currently ongoing to assess overall survival (OS), a secondary endpoint.

Price Action: BMY shares are trading flat at $59.09 on Friday.